
    
      Primary:

      • To assess safety, tolerability and efficacy of 2 dose strengths of ATI-50002 Topical
      Solution, compared to vehicle in subjects with alopecia areata (AA)

      Secondary:

      • To evaluate key clinical outcome assessments
    
  